These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37729954)

  • 1. Burden of pulmonary hypertension due to chronic obstructive pulmonary disease: Analysis of exacerbations and healthcare resource utilization in the United States.
    Klinger JR; Wu B; Morland K; Classi P; Fiano R; Grabich S
    Respir Med; 2023; 219():107412. PubMed ID: 37729954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis.
    Weiss T; Near AM; Zhao X; Ramey DR; Banerji T; Xie H; Nathan SD
    BMC Pulm Med; 2023 Nov; 23(1):455. PubMed ID: 37990203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
    Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COPD exacerbation frequency and its association with health care resource utilization and costs.
    Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
    Wan Y; Sun SX; Corman S; Huang X; Gao X; Shorr AF
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2127-36. PubMed ID: 26504378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS; DePietro M; McPheeters J; Fox KM
    Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
    Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Disease Burden and Healthcare Resource Utilization Among Patients with COPD and Asthma Using Triple Therapy (FF/UMEC/VI) in the United States.
    Igboekwe E; Verma S; Paczkowski R
    Int J Chron Obstruct Pulmon Dis; 2024; 19():281-296. PubMed ID: 38292138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population.
    Medrek SK; Sharafkhaneh A; Spiegelman AM; Kak A; Pandit LM
    COPD; 2017 Oct; 14(5):484-489. PubMed ID: 28715281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
    Sethi S; Make BJ; Robinson SB; Kumar S; Pollack M; Moretz C; Dreyfus J; Xi A; Powell D; Feigler N
    Int J Chron Obstruct Pulmon Dis; 2022; 17():593-608. PubMed ID: 35342290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short- and Long-Term Impact of Prior Chronic Obstructive Pulmonary Disease Exacerbations on Healthcare Resource Utilization and Related Costs: An Observational Study (SHERLOCK).
    de Nigris E; Haughney J; Lee AJ; Nath M; Müllerová H; Holmgren U; Ding B
    COPD; 2023 Dec; 20(1):92-100. PubMed ID: 36656661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 16. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study.
    Johansson G; Mushnikov V; Bäckström T; Engström A; Khalid JM; Wall J; Hoti F
    BMC Pulm Med; 2018 Jan; 18(1):17. PubMed ID: 29370846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [No Abstract]   [Full Text] [Related]  

  • 18. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
    Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
    J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo C; Yeap J; Wild R; Compton C; Rothnie KJ; Herth FJF; Quint JK; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2039-2054. PubMed ID: 37731774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
    Punekar YS; Shukla A; Müllerova H
    Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.